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It has been reported that prolactin (PRL) is cleaved to 14 or 16 kDa fragments by cathepsin D in vitro 
and in vivo,  and that such fragments exhibit antiangiogenic and proapoptotic properties.  The aim of 
this study was to investigate the relationship between pregnancy induced hypertension (PIH) and the 
placental expression of antiangiogenic PRL fragments and cathepsin D.  Placental expression of PRL 
fragments and cathepsin D was evaluated by Western blot analysis in a group of 9 pregnant women 
consisting of 5 normal pregnancies and 4 severe PIH cases.  Antiangiogenic PRL fragments were 
detected in 4 placental samples from all PIH cases but not detected in those from normal pregnancies 
(p＜0.05).  The expression of cathepsin D in PIH placentas was signiﬁcantly lower than that in those 
without PIH (p＜0.05),  while the placental expression of procathepsin D was signiﬁcantly greater in 
PIH cases than in the normal pregnancies (p＜0.05).  These data suggest that antiangiogenic PRL frag-
ments in the placenta may be present only in PIH cases,  and that PRL fragments in the placenta might 
be implicated in the pathophysiology of PIH.
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rolactin (PRL) is synthesized and excreted in 
the anterior pituitary and has a wide range of 
physiological eﬀects,  including eﬀects on osmosis,  
immunoregulatory function,  luteal function,  and sex-
ual behavior,  as well as mammary gland development 
and galactopoiesis during the lactational stage.
　 This hormone is also produced in many tissues in 
addition to the anterior pituitary and is known to act 
locally [1].  It has been reported that the normal 23 
kDa PRL has angiogenic action both in vitro and in 
vivo,  while the 14kDa and l6kDa PRL fragments 
cleaved from the 23kDa PRL under a low pH environ-
ment with cathepsin D,  which is lysosomal protease,  
have antiangiogenic and proapoptotic properties,  
respectively [2].
　 Pregnancy induced hypertension (PIH),  or preec-
lampsia,  is a major cause of maternal mortality and 
morbidities,  perinatal deaths,  preterm birth,  and 
intrauterine growth restriction,  and its mechanism has 
not been identiﬁed thoroughly [3].  PRL increases 
during pregnancy and the major circulating PRL iso-
form (23kDa) has angiogenic action while the 16kDa 
fragments resulting from proteolytic cleavage from 
23kDa PRL have antiangiogenic action.  Therefore,  it 
has been hypothesized that the balance between the 
23kDa PRL and 16kDa PRL plays an important role 
in the placenta and that if the 16kDa PRL becomes 
P
Acta Med.  Okayama,  2010
Vol.  64,  No.  4,  pp.  249ﾝ255
CopyrightⒸ 2010 by Okayama University Medical School.
Original Article http ://escholarship.lib.okayama-u.ac.jp/amo/
Received February 25, 2010 ; accepted May 12, 2010.
＊Corresponding author. Phone : ＋81ﾝ86ﾝ235ﾝ7320; Fax : ＋81ﾝ86ﾝ225ﾝ9570
E-mail : masuyama@cc.okayama-u.ac.jp (H. Masuyama)
There are no conﬂicts of interest.
predominant over the 23kDa PRL in the early stage 
of pregnancy,  this imbalance induces preeclampsia due 
to the shallow entry of the spiral artery [4,  5].
　 It has been reported that the levels of the 14 and 
16kDa antiangiogenic PRL fragments are increased in 
the urine and amnion liquid in preeclampsia cases,  and 
renal glomerulus and deciduas have been suggested as 
the source of these increases,  respectively [6,  7].  It 
is suspected that the PRL fragments are associated 
with PIH; however,  there has been no report of the 
increased PRL fragment expression in the placenta of 
women with PIH.
　 Cathepsin D is observed as a lysosomal protease in 
almost all cells,  tissues and organs [8] and processes 
PRL into N-terminal fragments such as 14kDa or 
16kDa PRL [2,  9].  Cleavage of PRL by cathepsin D 
generates N-terminal fragments that act on endothelial 
cells to suppress vasodilation and angiogenesis and 
promote vascular regression [10],  suggesting that the 
expression of cathepsin D might play an important role 
along with antiangiogenic fragments of PRL in the 
placenta.
　 The aim of this study was to investigate the rela-
tionship between PIH and the placental expression of 
antiangiogenic prolactin fragments and cathepsin D.
Materials and Methods
　 Reagents and chemicals. Unless otherwise 
speciﬁed,  all reagents and chemicals were purchased 
from Wako Pure Chemical Industries,  Ltd.  (Osaka,  
Japan).
　 Sample collection. The protocol of this study 
was approved by our instituteʼs review board.  All 
participants were admitted into our hospital,  and 
provided written informed consent.  Placental tissue 
biopsies were obtained during Cesarean section from 
9 pregnant women,  or 5 normal pregnancies and 4 
severe PIH cases.  All patients with PIH had severe 
new-onset hypertension which was deﬁned as systolic 
blood pressure more than or equal to 160mmHg and/
or diastolic blood pressure more than or equal to 
110mmHg and an age of 32 weeks or older,  while 
participants assigned to the control group were nor-
motensive.  Three of the patients with PIH had mas-
sive proteinuria [ｧ5g/day or ｧ300mg/dl] and the 
remaining patient did not.  Protein extracts from pla-
cental tissues were obtained using T-PER tissue pro-
tein extraction reagent (Pierce Chemical Co.,  
Rockford,  IL,  USA) according to the manufacturerʼs 
protocol and stored at －80℃ until analysis.
　Western blot analysis. Placental tissue 
extracts were separated on a 10-20ｵ (for PRL) or a 
10ｵ (for cathepsin D) SDS-PAGE gradient gel 
(System Instruments Co.,  Ltd.,  Tokyo,  Japan) along 
with molecular weight markers (Precision Plus 
Protein Kaleidoscope prestained standards; Bio-Rad 
Laboratories Inc.,  Hercules,  CA,  USA),  and subse-
quently transferred to polyvinylidene ﬂuoride mem-
branes (GE Healthcare UK,  Ltd.,  Buckinghamshire,  
UK).  Then,  total protein bands were visualized by 
Ponceau S (Sigma-Aldrich Co.,  St.  Louis,  MO,  
USA) staining of the membrane to conﬁrm equal pro-
tein loading.  Nonspeciﬁc protein binding was blocked 
with 8ｵ non-fat dry milk in Tris-buﬀered saline solu-
tion with 0.05ｵ Tween 20 (Sigma-Aldrich Co. ) 
(TTBS) for 2 h at room temperature.  The blots were 
incubated with either rabbit monoclonal antibody 
raised against PRL (1 : 800 dilution) (the generous gift 
of Dr. Ingrid Struman,  University of California 
School of Medicine,  San Francisco,  CA,  USA) or β
-actin (1 : 1000 dilution) (Santa Cruz Biotechnology,  
Inc.,  Santa Cruz,  CA,  USA) in TTBS with 3ｵ 
bovine serum albumin (BSA),  or mouse monoclonal 
antibody raised against cathepsin D (1 : 3000 dilution) 
(Abcam PLC,  Cambridge,  UK) or β-actin (1 : 1000 
dilution) in TTBS with 3ｵ BSA at 4℃ overnight.  
The blots were washed,  then incubated with goat anti-
rabbit secondary antibody (1 : 40000 dilution) (KPL 
Inc.,  Gaithersburg,  MD,  USA) for PRL and β-actin 
or goat anti-mouse secondary antibody (1 : 40000 dilu-
tion) (KPL Inc. ) for cathepsin D in TTBS for 2 
hours at room temperature.  The blots were then 
washed,  and speciﬁc signals were detected using 
SuperSignal West Pico chemiluminescent Substrate 
(Pierce Biotechnology Inc. ) according to the manufac-
turerʼs instructions.  The housekeeping gene β-actin 
was used to conﬁrm equal loading.  The amount of 
each protein was quantiﬁed densitometrically using an 
Image Scanner CanoScan D 2400U (Canon,  Tokyo,  
Japan) and Bio Image BQ 2.0 software (Bio Image,  
Ann Arbor,  MI,  USA).
　 Reverse transcription-polymerase chain reac-
tion (RT-PCR). Total RNA was extracted from 
placental tissues with or without PIH using Trizol 
reagent (Life Technology Inc.,  Grand Island,  NY,  
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USA).  Each sample was treated with DNase I to 
remove genomic DNA contamination.  To generate 
ﬁrst-strand DNA,  0.1µg of total RNA was reverse-
transcribed at 42℃ for 20min in 20µl of reaction 
solution containing 1xPCR buﬀer,  5mM MgCl2,  
1mM dNTPs,  2.5µM random 9-mer primer,  10U 
RNase inhibitor and 5U AMV reverse transcriptase,  
using an RNA PCR kit (TAKARA Co.,  Ltd.,  Kyoto,  
Japan) according to the manufacturerʼs protocol.  The 
primers used to amplify human PRL and GAPDH 
have been described previously [11].  Ampliﬁcation of 
PXR and GAPDH was carried out on a GeneAmp 
PCR system 9700 (Applied Biosystems,  Foster City,  
CA,  USA).  The number of PCR cycles resulting in 
PCR products in the linear logarithmic phase of the 
ampliﬁcation curve was determined.  PCR samples 
were electrophoresed on 3ｵ Nu-Sieve agarose gels 
and visualized by staining with ethidium bromide.  The 
housekeeping gene glyceraldehydes phosphate dehy-
drogenase (GAPDH) was used to control for varia-
tions in RNA recoveries from each specimen.
　 Statistical analysis. The data are presented as 
the mean±S.E.M.  Statistical analyses were per-
formed using the Mann-Whitney U-test and chi-square 
test for comparison between each groups.  The analy-
ses were performed with the software package 
StatMate III (Avice Inc.,  Tokyo,  Japan).  Diﬀerences 
were considered signiﬁcant at p＜0.05.
Results
　 Background of patients. The patients con-
sisted of 4 severe PIH cases and 5 control cases.  
There were no signiﬁcant diﬀerences between PIH and 
control patients with regard to maternal age,  the 
number of pregnancies,  parity,  BMI before preg-
nancy,  gestational week of delivery,  or birth weight.  
Small for gestational age (SGA) infants were observed 
in 3 out of 4 cases in the PIH group,  and the fre-
quency of SGA infants was signiﬁcantly higher in the 
PIH group.  As expected,  systolic and diastolic blood 
pressures and the frequency of small for gestational 
age infants were signiﬁcantly higher in women with 
PIH (Table 1).
　 Expression of 23-kDa PRL and 14 or 
16-kDa PRL fragments. The level of expression 
of 23kDa PRL was greater in the PIH group than in 
the control group; however,  the diﬀerence was not 
signiﬁcant (Fig.  1A).  RT-PCR analysis revealed that 
the expression of PRL mRNA in the PIH group was 
also greater than that in the control group (Fig.  1B).  
On the other hand,  the frequencies of the 14kDa and 
16kDa PRLs were signiﬁcantly higher in the PIH 
groups than in the control group,  where these PRLs 
were not observed at all (Fig.  2).
　 Expression of cathepsin D or procathepsin 
D. Mature cathepsin D of 34kDa is produced from 
48kDa cathepsin D of intermediate type processed 
from 52kDa procathepsin D [8].  The antibody used 
in the present study can detect isoforms of 52kDa,  
48kDa and 34kDa.  The level of mature cathepsin D 
(34kDa) was signiﬁcantly lower in the placentas of the 
PIH group compared with those of the control group 
(Fig.  3).  In contrast,  the intermediate form of cathe-
psin D (48kDa) was increased in the PIH group,  but 
not signiﬁcantly (Fig.  4),  and procathepsin D (52kDa) 
was signiﬁcantly increased in the placentas in the PIH 
group compared with the control group (Fig.  5).
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Table 1　 Clinical characteristics of pregnant women with severe PIH or normal pregnancies
Variable severe PIH (n＝4) control (n＝5) P value
Mean age ± SEM (yr) 34.3±3.73 34.2±0.8 NS
Mean gravidities ± SEM 1.75±1.44 0.71±0.32 NS
Mean parities ± SEM 1.5±1.5 1.4±0.2 NS
Mean body mass index ± SEM 27.1±2.6 22.4±1.9 NS
Mean gestational age at delivery ± SEM (wk) 35.0±0.58 32.6±1.6 NS
Mean infant birth weight ± SEM (g) 1,833±277 1,981±364 NS
No. of SGA infants 3　　 0　　 p＜0.05
Mean systolic blood pressure 179±4.07 111±3.23 p＜0.05
Mean diastolic blood pressure 105±2.4 60.8±3.68 p＜0.05
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Fig. 3　 Western blot analyses for 34kDa cathepsin D expression 
in the placental tissues of cases of PIH (n＝4) or normal pregnancy 
(n＝5).  The results represent the mean±S.E.M.  (＊p＜0.05).
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Fig. 5　 Western blot analyses for 52kDa procathepsin D expres-
sion in the placental tissues of cases of PIH (n＝4) or normal 
pregnancy (n＝5).  The results represent the mean±S.E.M. (＊p＜
0.05).
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Fig. 4　 Western blot analyses for 48kDa cathepsin D expression 
in the placental tissues of cases of PIH (n＝4) or normal pregnancy 
(n＝5).  The results represent the mean±S.E.M..
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Fig. 1　 A,  Western blot analyses for 23kDa PRL expression in 
the placental tissues of cases of PIH (n＝4) or normal pregnancy 
(n＝5).  The results represent the mean±S.E.M.; B,  Total RNA 
was also obtained from the placental tissues of cases of PIH (n＝
3) and normal pregnancy (n＝3) and analyzed for the expression of 
PRL and GAPDH mRNAs using RT-PCR.  PCR products were 
separated on 3% Nu-Sieve agarose gels and visualized by ethidium 
bromide staining.
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Fig. 2　 Western blot analyses for 14 or 16kDa PRL expression in 
the placental tissues of cases of PIH (n＝4) or normal pregnancy 
(n＝5).  
Discussion
　 PRL has various isoforms; the 23kDa PRL is the 
most prevalent and has normal physiological eﬀects 
[12].  In the present study we observed a higher level 
of 23kDa PRL expression in the PIH group relative 
to the control group,  but this diﬀerence was not sta-
tistically signiﬁcant.  However,  recent reports have 
demonstrated that there were no signiﬁcant diﬀer-
ences of 23kDa PRL in blood serums,  the urine and 
amniotic liquid between PIH cases and normal preg-
nant women [6,  13-15].  PRL fragments that are 
proteolytically cleaved from 23kDa PRL have been 
detected in human living bodies as well as in vitro and 
are reported to be associated with various disorders 
[2].  In the case of pregnancy,  it is reported that the 
fragments are observed in the blood sera of patients 
with postpartum cardiomyopathy or in the urine or 
amniotic liquid in preeclampsia cases [6,  7,  16].  
Leaños-Miranda et al.  reported signiﬁcant diﬀerences 
of PRL in the urine and that their isoforms appeared 
to be suitable markers to assess the severity of preec-
lampsia [7].  To our knowledge,  however,  there has 
been no report about PRL and its fragments in the 
placenta.  In this study,  we ﬁrstly observed that there 
was no signiﬁcant diﬀerence of 23kDa PRL expres-
sion,  but the signiﬁcant increase of antiangiogenic 
PRL fragments in the placentas of the PIH cases 
compared with those in the placenta of normal preg-
nancy.
　 In this study,  PRL fragments of 14kDa and 
16kDa were observed in all the placentas in the PIH 
group,  but not in the control group.  Isoforms of 14 
and/or 16kDa PRL fragments have previously been 
observed in the pituitary adenoma [9],  endothelial 
cells [17],  subretinal ﬂuid [18] and serum [18-21].  
Leaños-Miranda reported that no PRL fragments were 
observed in the urine of a control group,  and that the 
expression ratio of PRL fragments in severe preec-
lampsia cases was only 21.6ｵ,  which is not a particu-
larly high value [7].  González et al.  reported that 
PRL fragments in the amniotic liquid had signiﬁcantly 
large amounts of protein in preeclampsia cases.  There 
were some cases in which PRL fragments were 
observed in the amniotic liquid of cases without preec-
lampsia [6].  It is highly likely that the expression 
ratio of PRL fragments varies depending on the tis-
sues even in the PIH cases,  however,  that antiangio-
genic fragments of PRL might be dominant in the feto-
placental units,  including placenta and amniotic liquid,  
in PIH cases.
　 We measured the expression of cathepsin D,  which 
processes PRL to antiangiogenic fragments such as 
14kDa or 16kDa PRL under acid environments,  in 
the placenta.  Mature 34kDa cathepsin D is observed 
in almost all cells,  tissues and organs as a lysosomal 
protease and is produced from 48kDa cathepsin D of 
intermediate type processed from 52kDa procathepsin 
D [8].  In the present study,  the level of 52kDa pro-
cathepsin D was signiﬁcantly higher and the level of 
mature cathepsin D of 34kDa was signiﬁcantly lower 
in the patients with PIH than in the controls.  
Cathepsin D activity has been reported to be increased 
in the trophoblasts of their PIH subjects [6],  while 
an acidic environment existed in the placenta in 
patients with preeclampsia and placental hypoxia 
[22].  The lower level of cathepsin D and higher level 
of procathepsin D in PIH patients in the present study 
might indicate that PRL cleavage occurs with cathep-
sin D in the placenta under an acid environment due to 
the low oxygen levels and increase in cathepsin D 
consumption in the placentas of patients with PIH.  
However,  in addition to cathepsin D enzymatic activ-
ity,  recent reports have demonstrated that procathep-
sin D acted as a mitogen on both cancer and stromal 
cells and stimulated their pro-invasive properties,  and 
that the procathepsin D/cathepsin D level represented 
an independent prognostic factor in a variety of can-
cers,  including endometrial cancers and ovarian can-
cer [23].  Further analysis will be required to inves-
tigate the potential role of placental procathepsin D 
and cathepsin D in the pathophysiology of preeclamp-
sia,  including localization.
　 It has been reported that the 14kDa and 16kDa 
PRLs exhibit antiangiogenic and proapoptotic actions 
[2,  9].  An increase of 14kDa or 16kDa PRL in the 
placenta leads to decreased angiogenesis or increased 
apoptosis,  causing a hypoxic atmosphere.  As a result,  
cathepsin D is activated and production of PRL frag-
ments is increased.  Such conditions are probably 
associated with various complications,  including non-
reassuring fetal status,  which is caused by the placen-
tal dysfunction that frequently coexists with PIH,  
intrauterine growth restriction and placental abrup-
tion.
　 The present study suggests that the placenta is a 
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source of PRL fragments.  In addition to this study,  
other studies have reported that expression of the 14 
or 16kDa PRL is increased in the urine or amniotic 
liquid in preeclampsia cases,  and that these increases 
may be due to renal glomerulus and deciduas [6,  7].  
In addition to PIH or preeclampsia cases,  the possi-
bility of production of PRL fragments in retinopathy,  
in pituitary adenoma and in the hearts of postpartum 
cardiomyopathy has been reported [9,  15,  24].  In 
several fetal and maternal tissues,  including deciduas,  
placenta and kidney,  the PRLs upregulated during 
pregnancy are cleaved and processed to PRL frag-
ments,  and these fragments act as antiangiogenic and 
proapoptotic factors,  resulting in being associated 
with the expression of the disease state and the symp-
toms related to various PIH.  Because this study had 
a small sample size and only observed the placental 
expression of PRL and its fragments,  further studies 
will be needed to investigate the association of antian-
giogenic fragments of PRL with the severity of the 
PIH and the potential roles of PRL and antiangio-
genic fragments in the placenta of PIH cases.
　 In conclusion,  PRL fragments were shown to be 
increased in the placenta of PIH cases,  and the pla-
centa was suggested to be the source of the increase.  
Although further in vitro and in vivo study is necessary,  
we speculate that PRL fragments are associated with 
the pathophysiology of the placenta dysfunction in PIH 
cases.
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